Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 41812830.
- Also identified by DOI 10.1053/j.gastro.2026.01.047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The American Gastroenterological Association gathered a group of interdisciplinary experts to develop an updated Clinical Care Pathway on how to best screen for, diagnose, and treat metabolic dysfunction-associated steatotic liver disease. The complementary clinical application was also updated to reflect the changes in the clinical guidance: MASLD/MASH Clinical Care Pathway mobile application at gastro.org/MASLD.